Matching articles for "Beovu"
Issue 1719 · January 6, 2025
Drugs for Age-Related Macular Degeneration

Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).

Med Lett Drugs Ther. 2025 Jan 6; 67(1719):1-5 doi:10.58347/tml.2025.1719a
Age-related macular degeneration (AMD) has two major forms: dry or non-neovascular (~90% of patients) and wet or neovascular (~10% of patients).
Issue 1649 · May 2, 2022
A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related…

Med Lett Drugs Ther. 2022 May 2; 64(1649):71-2
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz) , a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June 2022.
Issue 1646 · March 21, 2022
Faricimab (Vabysmo) for Age-Related Macular Degeneration and Diabetic Macular Edema

Faricimab-svoa ( Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet)…

Med Lett Drugs Ther. 2022 Mar 21; 64(1646):45-6
Faricimab-svoa ( Vabysmo – Genentech), an inhibitor of both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), has been approved by the FDA for intravitreal treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). It is the first drug to become available in the US that targets two pathways involved in maintaining vascular homeostasis. Several VEGF inhibitors are available for treatment of nAMD and DME (see Table 2).
Issue 1593 · March 9, 2020 Free
Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration

We reviewed brolucizumab ( Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported…

Med Lett Drugs Ther. 2020 Mar 9; 62(1593):40
We reviewed brolucizumab ( Beovu – Novartis) for treatment of neovascular (wet) age-related macular degeneration in our February 10 issue. On February 23, the American Society of Retina Specialists reported that 14 patients who received the drug have developed retinal vasculitis, a potentially vision-threatening complication.
Issue 1591 · February 10, 2020
Brolucizumab (Beovu) for Age-Related Macular Degeneration

Brolucizumab-dbll ( Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular…

Med Lett Drugs Ther. 2020 Feb 10; 62(1591):23-4
Brolucizumab-dbll ( Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). It is the fourth VEGF inhibitor to be approved in the US for this indication; bevacizumab ( Avastin , and others), a VEGF inhibitor FDA-approved for treatment of breast cancer and other malignancies, has been used off-label for this indication for years.
Issue 1586 · December 2, 2019
Drugs for Common Eye Disorders

This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.

Med Lett Drugs Ther. 2019 Dec 2; 61(1586):187-94
This issue includes reviews of drugs for glaucoma, age-related macular degeneration (AMD), bacterial conjunctivitis, and dry eye disease. Allergic conjunctivitis is reviewed in a separate issue.